Sydney Grey
Concord, NCNPI 1912548140
Payments from drug & device makers
Across 311 payments — averaging $20.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$899
- Supernus Pharmaceuticals, Inc.$656
- Axsome Therapeutics, Inc.$608
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$492
- Otsuka America Pharmaceutical, Inc.$486
- Jazz Pharmaceuticals Inc.$445
- plus $3K from 24 others
What the payments were for
- Food & beverage$6,37998%
- Education$1032%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 58 | $899 |
| Supernus Pharmaceuticals, Inc. | 33 | $656 |
| Axsome Therapeutics, Inc. | 21 | $608 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 18 | $492 |
| Otsuka America Pharmaceutical, Inc. | 19 | $486 |
| Jazz Pharmaceuticals Inc. | 20 | $445 |
| Avadel CNS Pharmaceuticals, LLC | 16 | $366 |
| Neurelis, Inc. | 15 | $357 |
| Alkermes, Inc. | 14 | $308 |
| Corium, LLC | 12 | $238 |
| Collegium Pharmaceutical, Inc. | 11 | $206 |
| UCB, Inc. | 9 | $190 |
| Teva Pharmaceuticals USA, Inc. | 8 | $166 |
| Ironshore Pharmaceuticals Inc. | 8 | $150 |
| Lundbeck LLC | 8 | $142 |
| Neos Therapeutics, LP | 7 | $121 |
| Takeda Pharmaceuticals U.S.A., Inc. | 6 | $105 |
| Tris Pharma Inc | 5 | $99 |
| Idorsia Pharmaceuticals US Inc | 4 | $88 |
| Neurocrine Biosciences, Inc. | 5 | $78 |
| Johnson & Johnson | 2 | $57 |
| Noven Therapeutics, LLC | 3 | $46 |
| Harmony Biosciences LLC | 2 | $32 |
| Xeris Pharmaceuticals, Inc. | 1 | $32 |
| OWP Pharmaceuticals, Inc. | 1 | $24 |
| Sunovion Pharmaceuticals Inc. | 1 | $22 |
| Vertical Pharmaceuticals, LLC | 1 | $21 |
| Lilly USA, LLC | 1 | $16 |
| Almatica Pharma LLC | 1 | $16 |
| Azurity Pharmaceuticals, Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 96 | $3,330 |
| Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine | 34 | $2,524 |
| Methylphenidate ErMethylphenidate Hcl | 21 | $2,251 |
| Methylphenidate Hcl | 21 | $693 |
| Quetiapine Fumarate | 22 | $524 |
| Eszopiclone | 19 | $514 |
| Hydroxyzine Hcl | 24 | $427 |
| Clonazepam | 44 | $243 |
| Fluoxetine Hcl | 11 | $237 |
| Trazodone Hcl | 30 | $204 |
| Pramipexole DihydrochloridePramipexole Di-Hcl | 11 | $170 |
| Zolpidem Tartrate | 45 | $152 |
| Prazosin Hcl | 12 | $126 |
| Lamotrigine | 16 | $121 |
| Gabapentin | 11 | $91 |
Paid to pharmacies, not to this prescriber.
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.